This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, K. L.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 106 No. 5 November 2000, pp. 965-972

Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 Among Infants With Sickle Cell Disease

Received Mar 20, 2000; accepted Mar 23, 2000.

Katherine L. O'Brien*, Dagger , Andrea J. SwiftDagger , Jerry A. WinkelsteinDagger , Mathuram Santosham*, Dagger , Beth StoverDagger , Ruth Luddy§, Joseph E. Gootenbergparallel , Jeffrey T. Nold, Allen Eskenazi#, Sally J. SnaderDagger , Howard M. LedermanDagger , and for the Pneumococcal Conjugate Vaccine Study Group

From the * Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland; Dagger  Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland; § Sinai Hospital, Baltimore, Maryland; parallel  Georgetown University School of Medicine, Washington, DC;  Pediatric Center of Annapolis, Annapolis, Maryland; and the # University of Maryland School of Medicine, Department of Pediatrics, Baltimore, Maryland.

Objectives.  To determine the immunogenicity and safety of heptavalent pneumococcal polysaccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to CRM197 (7-valent conjugate pneumococcal vaccine [7VPnC]) among infants with sickle cell disease (SCD) and a comparison group of infants without SCD (non-SCD).

Design.  Two cohorts of infants were enrolled and received open-label doses of 7VPnC vaccine; infants enrolled before 2 months of age received 7VPnC vaccine at 2, 4, and 6 months of age followed by 23-valent pneumococcal polysaccharide vaccine (PS-23) at 24 months of age for those infants with SCD (schedule A), and infants enrolled between 2 and 12 months of age received 7VPnC at 12 months of age followed by PS-23 at 24 months of age for infants with SCD (schedule B). Safety data were collected for 3 days after each dose of vaccine. Antibody concentrations were measured to each of the 7VPnC serotypes by enzyme-linked immunosorbent assay before each vaccine dose and 1 month after the last 7VPnC dose and the PS-23 vaccine dose.

Results.  Forty-five infants (34 SCD and 11 non-SCD) were vaccinated according to schedule A and 16 infants (13 SCD and 3 non-SCD) according to schedule B. The 7VPnC vaccine was highly immunogenic for all serotypes among infants with and without SCD who received 3 doses of vaccine according to schedule A: depending on serotype, 89% to 100% achieved antibody concentrations above .15 µg/mL and 56% to 100% achieved antibody concentrations above 1.0 µg/mL. Among infants immunized according to schedule B, a single dose of 7VPnC vaccine resulted in antibody concentrations above .15 µg/mL in 53% to 92% by serotype and above 1.0 µg/mL in 31% to 71% by serotype. A single dose of PS-23 resulted in dramatic increases in the antibody concentrations to all serotypes regardless of 1- or 3-dose priming. There was no difference in the reactogenicity of the 7VPnC vaccine between those with and without SCD. There were no serious reactions to the 7VPnC or PS-23 vaccines, even among those with high antibody concentrations before immunization.

Conclusions.  Infants with SCD respond to 7VPnC vaccine with antibody concentrations that are at least as high as infants without SCD. Infants immunized with 7VPnC vaccine at 2, 4, and 6 months of age developed antibody concentrations in the same range as those achieved among infants without SCD enrolled in a large trial that demonstrated vaccine efficacy against invasive disease. Significant rises were seen in antibody concentrations to all 7VPnC serotypes after the PS-23 booster in children receiving schedule A or B.  Key words:  pneumococcus, sickle cell disease, conjugate vaccine, Prevnar.




This article has been cited by other articles:


Home page
 CVIHome page
E. A. Clutterbuck, S. Oh, M. Hamaluba, S. Westcar, P. C. L. Beverley, and A. J. Pollard
Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine
Clin. Vaccine Immunol., February 1, 2008; 15(2): 182 - 193.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. A. Rose, R. Schubert, N. Strnad, and S. Zielen
Priming of Immunological Memory by Pneumococcal Conjugate Vaccine in Children Unresponsive to 23-Valent Polysaccharide Pneumococcal Vaccine
Clin. Vaccine Immunol., October 1, 2005; 12(10): 1216 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. L. Lin, M. G. Michaels, M. Green, G. V. Mazariegos, S. A. Webber, K. S. Lawrence, K. Iurlano, and D. P. Greenberg
Safety and Immunogenicity of the American Academy of Pediatrics-Recommended Sequential Pneumococcal Conjugate and Polysaccharide Vaccine Schedule in Pediatric Solid Organ Transplant Recipients
Pediatrics, July 1, 2005; 116(1): 160 - 167.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
K. L. O'Brien and M. Santosham
Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases
Am. J. Epidemiol., April 1, 2004; 159(7): 634 - 644.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. I. Pelton and J. O. Klein
The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children
Pediatrics, October 1, 2002; 110(4): 805 - 814.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
A Finn, R Booy, R Moxon, M Sharland, and P Heath
Should the new pneumococcal vaccine be used in high-risk children?
Arch. Dis. Child., July 1, 2002; 87(1): 18 - 21.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
E. R. Wald
Pneumovax
Clinical Pediatrics, November 1, 2001; 40(11): 601 - 602.
[PDF]

Home page
 JWatch Infect. DiseasesHome page
How Well Does Conjugate Pneumococcal Vaccine Protect Infants with SCD?
Journal Watch Infectious Diseases, November 16, 2000; 2000(1116): 12 - 12.
[Full Text]